Modern Approaches to Studying the Mechanisms of Cognitive Impairment in Patients With Cardiovascular Diseases and the Possibility of their Correction
Keywords:
cognitive impairment, cardiovascular diseases, CeretonAbstract
With increasing life expectancy in modern society, the problem of age-related diseases is becoming urgent, among which cardiovascular diseases (CVD) and cognitive disorders occupy an important place. The article discusses the key pathogenetic mechanisms of cognitive impairment in elderly people with various cardiovascular diseases, such as hypertension, coronary heart disease, atrial fibrillation, chronic heart failure, and type 2 diabetes mellitus (DM2). The concept of diagnosis of chronic cerebral ischemia is highlighted and the prospects of the main therapeutic approaches aimed at improving cognitive functions in patients with CVD and type 2 diabetes are discussed. The spectrum of action and clinical effects of the drug Cereton (choline alfoscerate) are also analyzed in detail in this category of patients.
References
Grinin V.M., Shestemirova E.I. Demographic aging in Russia at the present stage. Bulletin of the Russian Academy of Medical Sciences 2015;70(3):348-54.
Putilina M.V. Comorbidity in elderly patients. S.S. Korsakov Journal of Neurology and Psychiatry 2016;5:106-11.
Shishkova V.N. There is an elderly comorbid patient at the reception: we set the accents. Consilium Medicum 2019;21(9):48-53.
Shishkova V.N. Cognitive impairments as a universal clinical syndrome in the practice of a therapist. Therapeutic Archive 2014;86(11):128-34.
Shishkova V.N. The importance of arterial hypertension in the development of brain damage – from mild cognitive impairment to dementia. Systemic hypertension 2014;11(1):45-51.
Shishkova V.N. Neuroprotection in patients with arterial hypertension: minimizing the unfavorable prognosis. Therapeutic Archive 2014;86(8):113-8.
Suslina Z.A., Varakin Yu.Ya., Vereshchagin N.V. Vascular diseases of the brain. Epidemiology. Fundamentals of prevention. Moscow: MEDpress-inform; 2009. 352 p.
Parfenov V.A. Dyscirculatory encephalopathy and vascular cognitive disorders. Moscow: IMA-PRESS; 2017. 128 p.
Jefferson AL, Benjamin EJ. Cardiovascular disease, cognitive decline and dementia. In: Vascular cognitive impairment in clinical practice. Wahlung L, Erkinjuntti T, Gauthier S, editors. Cambridge, UK: Cambridge University Press; 2009: 166-77.
O’Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, Bowler JV, Ballard C, DeCarli C, Gorelick PB, Rockwood K, Burns A, Gauthier S, DeKosky ST. Vascular cognitive impairment. The Lancet. Neurology 2003 Feb;2(2):89-98.
Pullicino PM, Hart J. Cognitive impairment in congestive heart failure? Embolism vs hypoperfusion. Neurology 2001 Dec;57(11):1945-6.
Trojano L, Incalzi RA, Acanfora D, Picone C, Mecocci P, Rengo F; Congestive Heart Failure Italian Study Investigators. Cognitive impairment: a key feature of congestive heart failure in the elderly. Journal of Neurology 2003 Dec;250(12):1456-63.
Georgiadis D, Sievert M, Cencetti S, Uhlmann F, Krivokuca M, Zierz S, Werdan K. Cerebrovascular reactivity is impaired in patients with cardiac failure. European Heart Journal 2000;21:407-13.
Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R; IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th ed. Diabetes Research and Clinical Practice 2019 Nov;157:107843.
Shestakova M.V., Vikulova O.K., Zheleznyakova A.V., Isakov M.A., Dedov I.I. Epidemiology of diabetes mellitus in the Russian Federation: What has changed in the last decade? Therapeutic Archive 2019;91(10):4-13.
Dedov I.I., Shestakova M.V., Galstyan G.R. Prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Diabetes mellitus 2016;19(2):104-12.
Shishkova V.N., Kapustina L.A. Features of cognitive impairment development in patients with type 2 diabetes mellitus and metabolic syndrome. Doctor 2018;9:3-10.
Ostroumova O.D., Surkova E.V., Shikh E.V., Rebrova E.V., Borisov M.S. Cognitive impairments in patients with type 2 diabetes mellitus: prevalence, pathogenetic mechanisms, effect of antidiabetic drugs. Diabetes mellitus 2018;21(4):307-18.
Zakharov V.V., Yakhno N.N. Cognitive disorders in old age and senility. Methodical manual for doctors. Moscow, 2005. 71 p.
Martynov A.I., Vertkin A.L., Danilov A.B., Kozlov I.G., Maksimova M.Yu., Mkrtumyan A.M., Putilina M.V., Solovyova E.Yu., Tabeeva G.R., Fedotova A.V. Consensus on the management of patients with chronic cerebral ischemia for internists and general practitioners. Therapy 2020;41(7):15-21.
Tkacheva O.N., Ostroumova O.D., Kotovskaya Yu.V., Krasnov G.S., Kochetkov A.I., Pereverzev A.P. Hypoglycemic drugs deprescribing in elderly and senile patients: the current state of the issue and an overview of the evidence base. Clinical Pharmacology and Therapy 2019;28(3):62-7.
